Loading clinical trials...
Loading clinical trials...
Phase I/IIa Dose Escalation Safety and Efficacy Study of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelium Cells Transplanted Subretinally in Patients With Advanced Dry-Form Age-Related Macular Degeneration (Geographic Atrophy)
Conditions
Interventions
OpRegen
Locations
7
United States
West Coast Retina Medical Group
San Francisco, California, United States
Cincinnati Eye Institute
Cincinnati, Ohio, United States
Mid Atlantic Retina
Philadelphia, Pennsylvania, United States
Hadassah Medical Center
Jerusalem, Israel
Rabin Medical Center
Petah Tikva, Israel
Kaplan Medical Center
Rehovot, Israel
Start Date
April 1, 2015
Primary Completion Date
December 31, 2021
Completion Date
January 31, 2031
Last Updated
April 27, 2026
NCT07440225
NCT05407636
NCT07308639
NCT07441642
NCT05913063
NCT07392255
Lead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions